Caris Life Sciences Quarterly Balance Sheet
NASDAQ: CAIHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Caris Life Sciences financial position
As of Jun 30, 2026, Caris Life Sciences reported total assets of $1.23 billion, up 28.7% from a year earlier against total liabilities of $637.9 million. Shareholders' equity stood at $591.7 million, or 48.1% of assets. It carried $393.2 million of debt.
The current ratio (current assets divided by current liabilities) was 5.53, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.66.
Summary generated from market data by MetaCap's automated system. Methodology
Caris Life Sciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | — | 819.90M | 796.27M | 753.22M | 718.93M | 31.20M | 63.95M | — | — |
| Short-Term Investments | 102.20M | 2.31M | 2.29M | 2.27M | 2.25M | — | 2.20M | — | — |
| Receivables | 116.89M | 90.52M | 112.14M | 26.70M | 50.89M | — | 88.24M | — | — |
| Total Current Assets | 1.06B | 1.01B | 997.80M | 854.25M | 833.32M | — | 215.73M | — | — |
| Property, Plant & Equipment | 95.72M | 82.67M | 63.17M | 64.00M | 61.31M | — | 67.82M | — | — |
| Goodwill | 19.34M | 19.34M | 19.34M | 19.34M | 19.34M | — | 19.34M | — | — |
| Total Assets | 1.23B | 1.16B | 1.13B | 984.57M | 955.06M | — | 343.73M | — | — |
| Accounts Payable | 85.99M | 69.80M | 39.21M | 29.00M | 28.73M | — | 27.79M | — | — |
| Short-Term Debt | 178.00K | 173.00K | 169.00K | 164.00K | 95.00K | — | 60.09M | — | — |
| Total Current Liabilities | 191.44M | 143.90M | 127.14M | 86.03M | 90.18M | — | 165.42M | — | — |
| Long-Term Debt | 392.97M | 381.40M | 378.82M | 376.30M | 373.61M | — | 319.44M | — | — |
| Total Liabilities | 637.89M | 568.90M | 548.36M | 506.21M | 502.15M | — | 620.92M | — | — |
| Shareholders' Equity | 591.73M | 593.49M | 577.31M | 478.36M | 452.90M | -2.60B | -2.50B | -2.44B | -2.36B |
| Retained Earnings | -2.55B | -2.55B | -2.55B | -2.63B | -2.66B | — | -2.47B | — | — |
| Total Debt | 393.15M | 381.57M | 378.99M | 376.46M | 373.71M | — | 379.53M | — | — |
| Net Cash (Debt) | -290.95M | 440.64M | 419.58M | 379.03M | 347.48M | 31.20M | -313.38M | — | — |
| Shares Outstanding | 282.58M | 282.65M | 282.53M | 282.10M | 281.09M | — | 36.50M | — | — |
This table shows 9 quarterly periods of Caris Life Sciences's balance sheet, from Q2 2026 back to Q2 2024, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow CAI's reporting calendar. What is a balance sheet?